The Research and Development market has seen the greatest changes over
the last 10 years within the industry. With big pharma wrestling to
adapt a formerly successful model that each year is producing decreased
levels of output, we are now amidst the middle of the cycle with a move
away from investing in single large-scale R&D sites to diversifying
interests across geographic regions, technologies and partnering firms.
This approach is leading itself to increased open innovation, out-licencing and in-licencing of technology, and outsourcing models that drive down development costs and even partnering and profit sharing arrangements.
The downsize of this approach has obviously been that it has decentralised regulation and increased the number of different methodologies used- meaning that many projects have a unique set of challenges and a greater degree of variants between timelines.
This model, however, has matured over the past couple of years and we are now seeing a solution that enables increased innovative output from the R&D industry, whilst maintaining a more standardized approach to R&D and, crucially, approaches to measure effectiveness and ROI.
This CPhI Pharma Insights Report examines the current trends in evaluation, adoption and partnering solutions that have been implemented across the industry to drive greater innovations and cost efficiencies.
This approach is leading itself to increased open innovation, out-licencing and in-licencing of technology, and outsourcing models that drive down development costs and even partnering and profit sharing arrangements.
The downsize of this approach has obviously been that it has decentralised regulation and increased the number of different methodologies used- meaning that many projects have a unique set of challenges and a greater degree of variants between timelines.
This model, however, has matured over the past couple of years and we are now seeing a solution that enables increased innovative output from the R&D industry, whilst maintaining a more standardized approach to R&D and, crucially, approaches to measure effectiveness and ROI.
This CPhI Pharma Insights Report examines the current trends in evaluation, adoption and partnering solutions that have been implemented across the industry to drive greater innovations and cost efficiencies.
No comments:
Post a Comment